The research showed that ImaginAb's CD8 zirconium-89 (Zr-89) IAB22M2C agent was well tolerated with no immediate or delayed side effects, according to the firm. The biodistribution of the agent also suggested that CD8+ T cell-rich tissues were successfully targeted. The observed targeting of tumor lesions indicates the agent may be helpful for assessing the accumulation of CD8+ T cells within tumors, the company said.
The tracer is currently in phase II clinical trials.
Copyright © 2019 AuntMinnie.com